CME

Faculty: David Rubin, MD

Faculty: Kimberly D. Orleck, PA-C

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

Faculty: David Rubin, MD

Faculty: Brooke Hodnick, PA-C, MPAS

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

Faculty: David Rubin, MD

Faculty: Jennifer Geremia, PA-C

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

Faculty: Diana Castro, MD

Faculty: Jonathan Strober, MD

Drs. Jonathan Strober and Diana Castro examine the diagnostic approach to generalized myasthenia gravis (gMG), with a focus on age-related differences in clinical presentation. They describe early signs in pediatric patients—such as ptosis and impaired extraocular movements—and contrast these with the fluctuating fatigue, bulbar involvement, and proximal muscle weakness more commonly seen in adults. The discussion includes practical strategies for diagnostic confirmation and highlights the role of antibody testing and the limitations of electrophysiologic studies in children. The faculty emphasize the importance of keeping MG in the differential diagnosis to minimize delays in recognition and treatment.

Faculty: Diana Castro, MD

Faculty: Jonathan Strober, MD

This discussion between Drs. Diana Castro and Jonathan Strober focuses on the clinical utility of patient stratification and antibody profiling in generalized myasthenia gravis (gMG). The conversation addresses how age of onset, antibody status (acetylcholine receptor, MuSK, LRP4), and comorbidities can influence diagnosis and management plans. The speakers highlight the limitations of current pediatric assessment tools and the implications of antibody status for access to targeted therapies. Practical considerations for repeat testing, use of modified clinical scales, and individualized communication strategies with pediatric patients and families are also examined, emphasizing the nuanced approach required in younger populations.

Faculty: Diana Castro, MD

Faculty: Jonathan Strober, MD

Drs. Diana Castro and Jonathan Strober discuss treatment strategies for generalized myasthenia gravis (gMG), focusing on pediatric and adolescent care. They review traditional therapies and newer agents, such as FcRn and complement inhibitors, highlighting the role of antibody status and considerations for thymectomy. The conversation also addresses monitoring challenges, including limitations of clinical scales and the importance of patient and caregiver input in assessing treatment response.

Faculty: Erin Bohula, MD, DPhil

Faculty: Lawrence Leiter

This program explores evolving strategies for low-density lipoprotein cholesterol (LDL-C) management in patients at high cardiovascular (CV) risk who have not yet experienced a myocardial infarction or stroke. Drs. Bohula and Leiter discuss unmet needs, shifting LDL-C targets, and emerging treatment strategies, including PCSK9 inhibitors and results from the VESALIUS-CV trial. The conversation highlights how early, intensive LDL reduction can meaningfully lower the risk of first CV events. Practical guidance is shared on risk assessment, statin optimization, evaluating and managing statin intolerance, and the use of combination lipid-lowering therapy.

Host: Andrew S. Bomback, MD, MPH

Guest: Kelly B. Chen, MSN, AGACNP-BC

Guest: Duvuru Geetha, MD

On-demand webcast on the latest advances in diagnosing and managing patients with IgA nephropathy (IgAN), including the current data on new and emerging IgAN therapies.

Host: Anne Marie Singh, MD

On-demand webcast on the role of interleukin (IL)-13 in atopic dermatitis pathophysiology and strategies for leveraging IL-13 inhibitors to address disease burden and improve patient outcomes.

Host: Emily D. Clark, DO

Guest: Tracey M. Piparo, PA-C, CAQ-PMHC, DFAAPA

Guest: Susan Scanland, MSN, CRNP, GNP-BC, CDP

Guest: Anthony J. Viera, MD, MPH

In this on-demand webcast, leading experts in brain health provide guidance for patient education, discussion, and management geared toward HCPs in primary care who are at the forefront of an aging population at risk of cognitive decline trying to plan for its future and for whom brain health is a topic of uttermost importance.